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Abstract: Histopathologic tumor regression grades (TRGs) after
neoadjuvant chemotherapy predict survival in diﬀerent cancers.
In bladder cancer, corresponding studies have not been con-
ducted. Fifty-six patients with advanced invasive urothelial
bladder cancer received neoadjuvant chemotherapy before cys-
tectomy and lymphadenectomy. TRGs were deﬁned as follows:
TRG1: complete tumor regression; TRG2: >50% tumor re-
gression; TRG3: 50% or less tumor regression. Separate TRGs
were assigned for primary tumors and corresponding lymph
nodes. The prognostic impact of these 2 TRGs, the highest
(dominant) TRG per patient, and competing tumor features
reﬂecting tumor regression (ypT/ypN stage, maximum diameter
of the residual tumor) were determined. Tumor characteristics in
initial transurethral resection of the bladder specimens were
tested for response prediction. The frequency of TRGs 1, 2, and
3 in the primary tumors were n=16, n=19, and n=21; cor-
responding data from the lymph nodes were n=31, n=9, and
n=16. Interobserver agreement in determination of the TRG
was strong (k=0.8). Univariately, all evaluated parameters
were signiﬁcantly (Pr0.001) related to overall survival; how-
ever, the segregation of the Kaplan-Meier curves was best for
the dominant TRG. In multivariate analysis, only dominant TRG
predicted overall survival independently (P=0.035). In transure-
thral resection specimens of the chemotherapy-naive bladder can-
cer, the only tumor feature with signiﬁcant (P<0.03) predictive
value for therapy response was a high proliferation rate. In con-
clusion, among all parameters reﬂecting tumor regression, the
dominant TRG was the only independent risk factor. A favorable
chemotherapy response is associated with a high proliferation rate
in the initial chemotherapy-naive bladder cancer. This feature
might help personalize neoadjuvant chemotherapy.
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In patients with muscle-invasive bladder cancer, the5-year survival rate after cystectomy and pelvic lym-
phadenectomy is 50%.1,2 To improve this result, neo-
adjuvant chemotherapy has been explored, which shows a
survival beneﬁt of 5% to 7% at 5 years in meta-analysis.3
In 2011, the long-awaited mature results of the random-
ized Medical Research Council/European Organisation
for the Treatment and Cure of Cancer trial validated that
neoadjuvant chemotherapy signiﬁcantly increased sur-
vival of bladder cancer patients.4 These data should shift
the paradigm toward routinely administered neoadjuvant
chemotherapy before surgery in muscle-invasive bladder
cancer, as stated by Bajorin and Herr.5 Consequently, as
the number of bladder cancers treated in this manner will
increase signiﬁcantly in the near future, the challenge
will be to deﬁne prognostic and predictive features in
surgical specimens of these tumors. Previous studies6–9
have used the ypTNM stages10 in cystectomy specimens
as a parameter for tumor response to neoadjuvant
chemotherapy and to predict survival. However, tumor
regression grades (TRGs), which quantify the histo-
pathologic extent of tumor response to chemotherapy,
have shown stronger prognostic impact than the ypTNM
stages in rectal11,12 and esophageal13–16 cancers. In blad-
der cancer, these studies are missing and features of the
initial chemotherapy-naive tumors that predict regression
are unknown.
The aim of the present study was to deﬁne histo-
pathologic TRGs for urothelial bladder cancer, to de-
termine their prognostic relevance, and to correlate
histopathologic characteristics of the initial tumor in the




From January 2000 to August 2011, 621 consecutive
patients with muscle-invasive urothelial cancer of the
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bladder underwent cystectomy with standardized bilateral
extended pelvic lymphadenectomy as a single procedure
at the Department of Urology, University of Bern.
Staging after initial diagnosis included chest x-ray, bone
scan, and computed tomography scan of the abdomen
and pelvis in all patients. Radiologically, lymph node
metastasis was presumed in the presence of pathologically
enlarged lymph nodes >1 cm in diameter. Whenever en-
larged lymph nodes were accessible to needle biopsy,
histologic/cytologic proof was obtained. Fifty-six patients
(15 women, 41 men) received neoadjuvant chemotherapy
because of locally advanced primary tumors (cT4,
n=15), radiologic suspicion of lymph node metastases
(n=39; 21 conﬁrmed by biopsies), or other reasons
(n=2). All patients underwent cystectomy with
standardized bilateral extended pelvic lymphadenectomy
in curative intent as a second procedure 6 weeks after
termination of the chemotherapy. Follow-up was done
according to a standard protocol at 3 and 6 months
postoperatively, then at 6-month intervals until 5 years
and yearly thereafter.
Neoadjuvant Chemotherapy
In all cases, the recommendation for neoadjuvant
chemotherapy was made by a multidisciplinary tumor
board. The standard treatment consisted of a median of 4
(range, 1 to 6) cycles of cisplatin and gemcitabine
(n=47). In patients with cisplatin contraindications
(creatinine clearance <60mL/min, poor performance
status, clinically relevant hearing loss or tinnitus, neuro-
pathy), carboplatin was used (n=8). One patient re-
ceived 4 cycles of methotrexate, vinblastine, doxorubicin,
and cisplatin (MVAC).
Surgical Technique
Pelvic lymph nodes were uniformly dissected as pre-
viously described.17 In short, all lymphatic and connective
tissues were meticulously removed bilaterally from the ex-
ternal iliac region up to the crossing of the ureter with the
commune vessels, from the obturator fossa and the internal
iliac region. The dissected tissue, ﬁxed separately in neutral
buﬀered formalin (4%), was submitted for pathologic
evaluation. The protocol of the cystectomy procedure has
been reported in detail earlier.18
Pathology
All tissue slides from each patient were reevaluated
independently for this study by 2 investigators experi-
enced in uropathology (A.F. and R.S.) blinded to out-
come data.
TURB specimens of 40 patients with muscle-invasive
urothelial carcinoma of the bladder were processed at the
Institute of Pathology, University of Bern, and the others
were processed at diﬀerent pathology departments in
Switzerland. Microscopically, the following tumor charac-
teristics were evaluated for response prediction to neo-
adjuvant chemotherapy: grade, squamous or glandular
diﬀerentiation,7 nuclear anisocaryosis (maximum size >4
lymphocytes), and tumor-associated inﬂammation (tumors
with absent or scant inﬂammatory reaction were considered
negative, whereas tumors with moderate or intense in-
ﬂammatory reaction were considered positive).19 Purely
nonurothelial carcinomas (eg, adenocarcinoma and squ-
amous carcinomas) were excluded for analyses. Finally, to
assign a mitotic activity to the tumor, the proliferative hot
spot was identiﬁed, and here the number of mitotic ﬁgures
was counted in a high-power ﬁeld (diameter of the visual
ﬁeld: 0.54mm) as done by others.20 All cystectomy and
lymphadenectomy specimens were processed and evaluated
at the Institute of Pathology, University of Bern. All tissues
were ﬁxed in neutral buﬀered formalin (4%) for approx-
imately 24 hours. Characteristics of bladder lesions (re-
sidual tumors, ulcers, scars) were described (location, size,
relation to the bladder wall and surrounding tissues), and
corresponding tissue samples were taken for histologic ex-
amination. Whenever no residual cancer was detected, the
area of the tumor bed was totally embedded. Routinely,
samples from the bladder neck with trigone, dome, anterior
and posterior wall, and the resection margins of ureters and
urethra were embedded. Microscopically, tumor grade and
tumor stage were noted. Scoring of regression is described
in detail in the next paragraph. The maximum diameter of
the largest residual primary tumor focus was determined.
The lymph node specimens of each anatomic location were
examined by inspection and palpation separately, and all
macroscopically detected lymph nodes were embedded
completely. Whenever no lymph nodes were found, the
entire tissue was embedded for histologic examination. One
hematoxylin and eosin-stained section was taken per tissue
block, and no immunostaining analyses were performed
routinely. All tumors and lymph node metastases were
staged according to the seventh International Union
Against Cancer classiﬁcation of 2009.10 The use of patient
material was approved by the local ethics committee.
Morphologic Determination of the TRG
The TRG was based on a histologic estimations of
the size of the residual viable cancer tissue in relation to the
size of the original tumor bed, indicated by zones of ﬁb-
rosis in the bladder wall and in the perivesical soft tissue.
The zones of regression (Figs. 1, 2) in general showed a
tumor bed consisting of dense ﬁbrosis without cancer cells.
Sometimes edema was noted in these areas. Regularly ac-
cumulations of macrophages were present focally. In ad-
dition, inﬂammatory inﬁltrates with lymphocytes and
rarely eosinophilic and neutrophilic granulocytes were of-
ten seen in these zones. Regressive changes in lymph node
metastases (Figs. 3A–C) were comparable to changes in
primary tumors; however, in addition, the macrophages
could fill the entire tumor bed of resorbed metastases.
Larger zones of necrotic tumor cells, indicative of che-
motherapy effect, were infrequently seen probably due to
the long duration between the first cycle of chemotherapy
and the surgical procedure, which was performed in gen-
eral 6 weeks after the last cycle. In addition, very rarely,
cytoplasmic vacuolation and small groups of apoptotic
cells were observed in the residual neoplastic tissue, but
these minimal cytologic changes were not specific.
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TRGs were deﬁned in analogy to Mandard et al16
but with condensed grades as done by others21:
TRG1: Complete response: Absence of histologically identiﬁable
residual cancer cells and extensive ﬁbrosis of the tumor bed
(Figs. 1, 2).
TRG2: Strong response: Predominant ﬁbrosis of the tumor bed and
residual cancer cells occupying <50% of this area (Fig. 4).
TRG3: Week and no response: Predominant residual cancer cells
outgrowing tumor bed ﬁbrosis (Z50% of this area occupied
by cancer cells) or absence of regressive changes (Fig. 5).
2mm
FIGURE 1. Fibrotic scar without cancer cells (TRG1) in the
submucosa, muscularis propria, and perivesical tissue (arrows)
representing the original primary tumor bed (Masson
trichrome).
FIGURE 2. Higher magnification shows a dense fibrosis and





FIGURE 3. Completely regressed lymph node metastases with-
out cancer cells indicated by a nodular fibrotic zone in A (HE), by
a nodular accumulation of macrophages in B (HE), and by a
nodular zone of necrosis surrounded by granulation tissue and
fibrosis in C (HE). HE indicates hematoxylin and eosin.
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This grading system was used separately for primary
tumors and lymph node metastases. All of our patients
showed only 1 invasive primary cancer that was assigned
a TRG. Rarely, we observed, in addition, noninvasive
papillary tumors or carcinomas in situ. These lesions were
not considered for tumor regression. Lymphadenectomy
specimens without histologic evidence for prior meta-
stases were assigned TRG1*, those with ﬁbrotic zones
indicative of completely regressed metastases were as-
signed TRG1+, and both constituted the nodal TRG1
group. In patients with several lymph node metastases,
each could show diﬀerent amounts of regression
(Figs. 6A, B), and the average regression determined the
TRG. Finally, for every patient the “dominant” TRG,
which is the higher TRG between primary tumor and
lymph nodes, was determined.
Statistical Analyses
Interobserver variability in determination of the
TRG was measured by the Cohen k. Discrepant cases
were reevaluated, and a consensus was always reached.
The 3 TRGs were compared with regard to histopatho-
logic and clinical characteristics using a 2-sided Wilcoxon
rank sum test (for continuous, non-normally distributed
data) and the Fisher exact test (categorical data). Kaplan-
Meier plots and log rank tests were used to estimate
overall survival (OS) from surgery to the date of death.
Patients still alive were censored at the date of last follow-
up. Cox proportional hazards regression models were
used to determine the eﬀect of each variable on survival
time in a multivariate setting. Hazard ratios and 95%
conﬁdence intervals were estimated. A forward selection
procedure was used to investigate the eﬀect of each var-
iable on outcome while adjusting for the remaining po-
tential confounding variables entered into the model. A
signiﬁcance level of 0.05 was used for all tests. All sta-
tistical analyses were performed using SPSS 20.0 software
(SPSS Inc., Chicago, IL).
RESULTS
The Cohort
Clinical and histopathologic baseline data of the co-
hort are given in Table 1. At the time of cystectomy, 16
patients had no residual primary tumor (ypT0) and 31
patients no lymph node metastases (ypN0) upon histologic
examination. Median OS for the entire cohort was 3.7
years; 5-year OS was 49%. Median follow-up was 3.7 years.
For every patient, the corresponding TRG in the
primary tumors and in the lymph nodes are given
in Table 2. Half of the patients had concordant TRGs in
their primary tumors and lymph nodes (n=28). Dis-
cordant TRGs (n=28) mostly showed a trend for
stronger regression in the metastases than in the primary
tumors. The highest (dominant) TRG was TRG1 in 15
patients (27%), TRG2 in 16 patients (29%), and TRG3 in
25 patients (44%). Interobserver agreement in determi-
nation of the TRGs was strong (k=0.8).
Analyses of TRG With Histopathologic and
Clinical Characteristics
The TRGs in the primary tumor were positively
correlated with the ypT stages and maximum diameter of
the residual primary tumor, the lymph node TRGs with
the ypN stages, and the dominant TRGs with all these
tumor features (P<0.001 each). Indication for neo-
adjuvant chemotherapy, pretherapeutic clinical tumor,
2 mm
FIGURE 4. Residual cancer cells (arrows) in a predominant
fibrotic tumor bed (TRG2, Masson trichrome).
2 mm
FIGURE 5. Abundant residual cancer cells infiltrating the
bladder wall (arrows, hematoxylin and eosin). No relevant
tumor regression present (TRG3).
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and lymph node stages were not diﬀerent when compared
between dominant TRGs (P>0.5).
Univariate and Multivariate Survival Analyses
In univariate analyses, all tested tumor parameters
from the bladder and the lymph nodes related to tumor
regression stratiﬁed survival signiﬁcantly (Pr0.001,
Figs. 7A–E). Importantly, the segregation of the curves
was best for the dominant TRG, which factors in
the higher TRG from a primary tumor and the corre-
sponding lymph nodes (Fig. 7F). Number of identified
lymph nodes (P=0.3), indication for neoadjuvant
chemotherapy (P=0.8), pretherapeutic clinical tumor
(P=0.8), and lymph node (P=0.4) stages failed to
stratify survival.
The dominant TRG was the only independent risk
factor in multivariate analyses (P=0.035; Table 3) and
was the only parameter that was signiﬁcant in forward
stepwise calculation (P=0.001, hazard ratio 3.5, con-
ﬁdence interval 1.9-6.6). All other evaluated parameters
related to tumor regression failed to add independent
prognostic information.
Histopathologic Features in TURB Specimens
and Response to Chemotherapy
Finally, we evaluated various histopathologic tumor
features in chemotherapy-naive TURB specimens of com-
plete responders (dominant TRG1) and partial/non-
responders (dominant TRG2/TRG3). Complete responders
had a signiﬁcantly higher number of mitotic ﬁgures per
high-power ﬁeld (median: 4, range: 1 to 7, P<0.03; Fig. 8)
compared with partial/nonresponders (median: 2, range:
1 to 6). The prevalence of all other evaluated parameters in
the tumors including squamous and glandular diﬀer-
entiation was similar in these subgroups.
DISCUSSION
The rationale for neoadjuvant chemotherapy before
surgery is to treat micrometastatic disease early, under
FIGURE 6. Patients may have completely regressed lymph
node metastasis (A) next to ones (B) without regression
(hematoxylin and eosin).
TABLE 1. Clinicopathologic Data of the 56 Patients
Age (median [range]) at surgery (y) 63
(35-78)
Follow-up (median) (y) 3.7
Median OS (y) 3.7
Indication for neoadjuvant chemotherapy (n)
Clinically positive lymph nodes (biopsy proven) 39 (21)
Advanced primary tumor stage cT3/4 15
Other 2






Diameter of residual tumor per patient
(median [range]) (n)
0.5 (0-6)
Evaluated nodes per patient
(median [range]) (n)
31 (8-85)
Positive nodes per patient
(median [range]) (n)
0 (0-37)









TRG1* 15 (7*) 12 (6*) 4 (1*)
TRG2 1 2 6
TRG3 0 5 11
*Number of cases with clear-cut evidence for complete cancer regression in the
nodes in the form of larger foci of compact ﬁbrosis with inﬂammatory inﬁltrates.
The other cases always had smaller zones of ﬁbrosis in their lymph nodes, what is
normal in the pelvic nodes of elderly patients, and could not be assessed con-
clusively for regressed micrometastatic disease.
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FIGURE 7. A, OS stratified according to the TRG of the primary tumors, (B) the TRG of the lymph nodes (TRG1*: lymph
nodes without evidence of prior metastases; TRG1+: lymph nodes with complete regression of prior metastases), (C) ypT
stage, and (D) ypN stage shows better outcome in patients with lower stages. E, OS according to the largest diameter of
residual primary tumor shows better outcome in patients with smaller tumors. F, Best segregation is achieved when using
the dominant TRG, which is defined as the higher of both TRG assigned to the primary tumor and the corresponding lymph
nodes, respectively.
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relatively good performance status, and to downsize the
primary tumor for better operability.22 Such multi-
modality treatment is a standard procedure in cancers of
the rectum23 and esophagus24 to improve survival. For
these primary tumors elaborated histopathologic TRGs
with prognostic relevance exist.11,12,14–16 However, such a
concept has never been explored in bladder cancer.
Therefore, we deﬁned TRGs in analogy to the method
used in esophageal cancer16 and expanded the assessment
of tumor regression on the lymph node compartment.
The prognostic ability of the TRGs was tested in a uni-
formly treated cohort of 56 patients with advanced
bladder cancer. All patients underwent platin-based ne-
oadjuvant chemotherapy, followed by cystectomy with
standardized bilateral extended pelvic lymphadenectomy
at a single-center institution.
The TRG was based on estimations of the size of
the residual viable cancer tissue in relation to the size of
the original tumor bed. This system with 3 grades is
simple, highly reproducible, and allows the comparison of
regression grades between primary tumors and lymph
nodes. In 50% of the patients, the TRG determined in the
primary tumor and in the lymph nodes was identical.
Interestingly, the remaining patients showed discordant
TRG with more frequently lower TRG in the lymph
nodes than in the primary tumors. Therefore, response of
the primary tumor does not necessarily mirror the eﬀects
in the metastases. This information is important because
early assessment of tumor response by TURB after ﬁrst
cycles of neoadjuvant chemotherapy to identify non-
responders25,26 might be misleading.
The TRGs were outstanding prognostic factors. The
survival curves according to the TRG of the primary
tumors segregated better than those obtained from the
ypT stages; the nodal TRG could stratify outcome of the
pN0 group for patients with and those without evidence
of prior metastases. Importantly, survival stratiﬁcation
further improved when the higher (dominant) TRG from
both components, the primary tumors and the lymph
nodes, was taken into account: 80% of the complete
responders (dominant TRG1) showed long-term survival,
whereas only 15% of the weak/nonresponders (dominant
TRG3) survived 5 years postoperatively. The survival
curve of strong but incomplete responders (dominant
TRG2) was perfectly situated intermediately between
these 2 extremes. In multivariate analyses, the dominant
TRGs were better prognosticators than the pT and pN
stages, which failed to add independent prognostic in-
formation.
Administration of neoadjuvant chemotherapy in
bladder cancer has slowly risen over the last decade27;
however, its application in 3.1%28 to 9%27 of bladder
cancer patients is still low. Importantly, the long-term
results of the Medical Research Council/European
Organisation for the Treatment and Cure of Cancer study
might accelerate the shift to multimodal therapy: patients
receiving neoadjuvant chemotherapy before cystectomy
had a signiﬁcant survival beneﬁt of 26% compared with
patients undergoing cystectomy alone.4 The future central
issue will be to select patients who will respond to neo-
adjuvant chemotherapy. Separation of patients who
beneﬁt from those who do not will improve its acceptance
and avoid overtreatment. Therefore, we correlated his-
tomorphologic characteristics of the chemotherapy-naive
tumors received as TURB specimens with the TRGs. The
only parameter with predictive value for treatment re-
sponse was the proliferation rate. High proliferation rate
of the tumor was associated with complete tumor re-
sponse to chemotherapy. This is in line with data from the
North American Southwest Oncology Group bladder
cancer trial published by Grossman et al,29 which showed
better outcome in patients with high compared with low
tumor proliferation when treated by neoadjuvant che-
motherapy and cystectomy. The underlying rationale
might be the well-known cytotoxicity of cisplatin and
analogous primarily in proliferating cells.30 In contrast to
the North American Southwest Oncology Group trial,7
squamous or glandular diﬀerentiation was not associated
with response to neoadjuvant chemotherapy in our study.
There are limitations in our study that are due to its
retrospective character, with only patients having ad-
vanced, mostly metastasized tumors being included in
the study. This restricts conclusions to the high end of the
spectrum of invasive urothelial bladder cancers. Before
TABLE 3. Multivariate Analysis: Dominant TRG Was the Only
Independent Risk Factor for Overall Survival (OS)
OS
HR 95% CI P
TRG 4.0 1.1-14.9 0.035
ypN-stage 0.3 0.8-2.4 1.4
ypT-stage 0.9 0.4-1.8 0.7
Diameter of residual tumor* 0.8 0.2-3.7 0.7
*Dichotomized according to median (> median vs. r median).
CI indicates conﬁdence intervals; HR, hazard ratio.
p<0.03





























FIGURE 8. Boxplots show a significantly higher mitotic rate in
the initial tumor biopsies from complete responders (domi-
nant TRG1) compared with partial/nonresponders (dominant
TRG2/TRG3).
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using the TRGs routinely, as well as in populations
with earlier cancers, particularly in cT2 tumors, their
prognostic relevance has to be validated prospectively. In
these tumors, the diﬀerentiation of a tumor bed depleted
from neoplastic cells after neoadjuvant chemotherapy,
and post-TURB scarring might be more problematic than
in our cohort of advanced T3 and T4 bladder cancers,
which cannot be completely resected and in which the
eﬀect of this surgical procedure should be equally dis-
tributed over all groups of TRG. Finally, the limited scale
of our cohort might have obscured a potential impact of
squamous and glandular diﬀerentiation on tumor re-
sponse, as reported by Scosyrev et al.7
In conclusion, the method suggested for TRG de-
termination in neoadjuvantly treated bladder cancer
predicts survival independently and better than the ypT
and ypN stages. A high mitotic rate in the chemotherapy-
naive bladder cancer is signiﬁcantly associated with fa-
vorable chemotherapy response. This parameter might
help predict tumor response and personalize neoadjuvant
chemotherapy.
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